DeepMed Research

University of Minnesota Masonic Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig

Phase 1

Completed

Conditions: Lymphoma
Multiple Myeloma

Interventions: Biological: CMV-MVA Triplex Vaccine

First Posted Date: 2017-12-26

Last Posted Date: 2021-08-17

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 28

Registration Number: NCT03383055

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases

Phase 2

Terminated

Conditions: Thalassemia
High Risk Hematologic Disorders
Cerebral Adrenoleukodystrophy
Sickle Cell Disease
Inherited Metabolic Disorders

Interventions: Procedure: Blood and Marrow Transplant

First Posted Date: 2017-12-08

Last Posted Date: 2024-07-12

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 5

Registration Number: NCT03367546

Locations: 🇺🇸
Masonic Caner Center at University of Minnesota, Minneapolis, Minnesota, United States

QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML

Phase 2

Withdrawn

Conditions: High-Risk Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia
Treatment-Related Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Biological: ALT-803

First Posted Date: 2017-12-07

Last Posted Date: 2018-11-09

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Registration Number: NCT03365661

Locations: 🇺🇸
Masonic Cancer Center, Minneapolis, Minnesota, United States

Gut Microbiota in Intestinal Barrier Damage in Acute Leukemia Patients Undergoing Inpatient Induction

Completed

Conditions: Chemotherapy-Induced Gut Barrier Damage
Acute Leukemia

First Posted Date: 2017-10-20

Last Posted Date: 2019-05-06

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 20

Registration Number: NCT03316456

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Phase 2

Recruiting

Conditions: High Risk Anemia
Small Lymphocytic Lymphoma
Mantle-Cell Lymphoma
MRD Positive Leukemia
Plasma Cell Leukemia
Refractory Anemia
Natural Killer Cell Malignancies
Acute Leukemia
Acute Lymphoblastic Leukemia
Lymphoma

Interventions: Biological: HSCT with TBI Regimen
Biological: HSCT with Non-TBI Regimen

First Posted Date: 2017-10-19

Last Posted Date: 2025-02-04

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 300

Registration Number: NCT03314974

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

Phase 1

Withdrawn

Conditions: Brain Metastases
Metastatic Melanoma
Pulmonary Metastases
Hepatic Metastases

Interventions: Drug: Interleukin-2 & Ipilimumab (P-Ib)
Drug: Interleukin-2 & Ipilimumab (P-II)

First Posted Date: 2017-09-29

Last Posted Date: 2018-08-01

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Registration Number: NCT03297463

Locations: 🇺🇸
Masonic Cancer Center - University of Minnesota, Minneapolis, Minnesota, United States

BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy

Phase 2

Completed

Conditions: Muscle Invasive Bladder Cancer

Interventions: Drug: Nivolumab
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2017-09-27

Last Posted Date: 2021-12-16

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 43

Registration Number: NCT03294304

Locations: 🇺🇸
Masonic Cancer Center - University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
Huntsman Cancer Institute - University of Utah Health, Salt Lake City, Utah, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int

Phase 1

Completed

Conditions: Epithelial Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions: Biological: FATE-NK100
Drug: Interleukin-2

First Posted Date: 2017-07-11

Last Posted Date: 2021-03-12

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 10

Registration Number: NCT03213964

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Auto Stem Cell Transplant for Lymphoma Patients

Phase 2

Recruiting

Conditions: Hodgkin Lymphoma
Non-Hodgkin Lymphoma

Interventions: Procedure: Peripheral blood stem cell transplantation
Drug: Etoposide
Biological: G-CSF
Drug: BCNU
Drug: Cyclophosphamide
Drug: AraC
Drug: Melphalan
Radiation: Total Body Irradiation

First Posted Date: 2017-04-24

Last Posted Date: 2024-11-04

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 150

Registration Number: NCT03125642

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML

Phase 1

Completed

Conditions: Refractory Acute Myelogenous Leukemia
Relapsed Acute Myelogenous Leukemia

Interventions: Biological: FATE-NK100

First Posted Date: 2017-03-16

Last Posted Date: 2021-03-12

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 6

Registration Number: NCT03081780

Locations: 🇺🇸
University of Minnesota, Masonic Cancer Center, Minneapolis, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy